NEW HOPE, Pa., November 5, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). All of the securities are being offered by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock sold in the Offering at the public offering price per share, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
|
Orchestra BioMed Holdings, Inc. is a biomedical innovation company developing therapeutic products for procedure-based medicine, focusing on hypertension and atherosclerotic artery disease. The company’s flagship product candidates include Atrioventricular Interval Modulation (AVIM) Therapy, a bioelectronic treatment for hypertension that integrates as a firmware upgrade to cardiac pacemakers, and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug/device combination for artery disease that delivers an extended-release formulation of sirolimus during balloon angioplasty. Orchestra BioMed operates through strategic collaborations with medical device manufacturers, holding an exclusive license and collaboration agreement with Medtronic for the development and commercialization of AVIM Therapy. The company is conducting the BACKBEAT global pivotal study for AVIM Therapy and the Virtue Trial for Virtue SAB in the United States. Founded in 2018, the company utilizes a partnership-enabled business model to drive global commercialization of its late-stage clinical product candidates. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage orchestrabiomed.com |
| Sector Healthcare | IR page investors.orchestrabiomed.com/news-and-events | |
|
Tags
bioelectronic medicine, hypertension, cardiac pacemakers, drug-coated balloons, angioplasty, atherosclerotic artery disease, sirolimus, clinical trials, AVIM Therapy, Virtue SAB, Sirolimus EFR, BACKBEAT study, Virtue Trial, Moderato, Medtronic, Terumo, Boston Scientific, AGENT, Azure, Astra
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 307.265M |
| Market cap (USD) | $ 307.265M |
| P/E | -6.85 |
| PEG | — |
| P/BV | 39.48 |
| P/S | 9.85 |
| P/OCF | -4.85 |
| P/FCF | -4.79 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -121.8% |
| ROI | -76.9% |
| ROIC | -56.7% |
| Profit margin | -157.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 36.4% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 11 |
| Quality score | -53.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Trade receivables (USD) | — | — | 96,000 | 99,000 | 92,000 | 95,000 |
| ↳ YoY growth | +3.1% | -7.1% | +3.3% | |||
| Lease liabilities (USD) | — | — | 2.38M | 1.69M | 2.24M | 1.69M |
| Cash and deposits (USD) | 2.03M | 1.75M | 175,161 | 30.6M | 22.3M | 34.7M |
| Right-of-use assets (USD) | — | — | 2.19M | 1.56M | 2.1M | 1.5M |
| Cash flow detail | ||||||
| Operating cash flow (USD) | — | -272,362 | -1.58M | -46.1M | -50.6M | -49M |
| Purchases of property, plant and equipment (USD) | — | — | -591,000 | -78,000 | -289,000 | -489,000 |
| Change in receivables (cash effect) (USD) | — | — | 25,000 | -3,000 | 22,000 | -3,000 |
| Change in inventories (cash effect) (USD) | — | — | -208,000 | 131,000 | -28,000 | -137,000 |
| Change in payables (cash effect) (USD) | — | -12,422 | 375,542 | 145,000 | 2.97M | 4.87M |
| Interest paid (cash effect) (USD) | — | — | -1.37M | -1.12M | -102,000 | -1.45M |
| Share-based compensation (USD) | — | — | 3.38M | 7.63M | 10.6M | 12M |
| Operating cash flow before change in receivables (USD) | — | — | -29.3M | -46.1M | -50.6M | -49M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | — | -29.9M | -46.2M | -50.8M | -49.5M |
| Income detail | ||||||
| Research and development expense (USD) | — | — | 21.9M | 33.8M | 42.8M | 58.2M |
| Total comprehensive income (USD) | — | — | -33.6M | -49.1M | -61M | -52.7M |
| Comprehensive income to owners (USD) | — | — | -33.6M | -49.1M | -61M | -52.7M |
| Reported | Mar 10, 2021 | Mar 31, 2022 | Mar 27, 2024 | Mar 27, 2024 | Mar 31, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
October 29, 2026
-
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.
-
Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels substantially exceeding those achieved by drug-eluting stents and drug-coated balloons.
-
The Virtue Trial, a pivotal, head-to-head, randomized controlled IDE trial of Virtue SAB versus a commercially available drug-coated balloon in coronary in-stent restenosis, is currently enrolling.
NEW HOPE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that its Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) will be featured in a presentation at Transcatheter Cardiovascular Therapeutics (“TCT”) 2026. TCT, the Cardiovascular Research Foundation’s annual scientific symposium and the world’s premier educational meeting in interventional cardiovascular medicine, will take place October 31–November 3, 2026, at the San Diego Convention Center in San Diego, California.
The presentation will be delivered by Allen Jeremias, MD, Co-Principal Investigator of the Virtue Trial and Director of Interventional Cardiology Research and Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center. Dr. Jeremias will review the differentiated mechanism of action of Virtue SAB, the preclinical and clinical evidence supporting it, and the design of the Virtue Trial, the Company’s actively enrolling U.S. Investigational Device Exemption (“IDE”) pivotal trial comparing Virtue SAB head-to-head with the AGENT™ paclitaxel-coated balloon for the treatment of coronary in-stent restenosis (“ISR”) (NCT07045194).
Presentation Details
The Virtue Sirolimus AngioInfusion Balloon (SAB): Differential Mechanism, Clinical Benefit, and Pivotal IDE Trial Design (Sunday, November 1, 2026, 9:03–9:10 a.m. PT)
-
Session: TCT Innovation 2: Innovations in Intravascular Imaging and Coronary Technologies
-
Location: Innovation Theater, Sails Pavilion, Upper Level, San Diego Convention Center
-
Presenter: Allen Jeremias, MD
The presentation will focus on three key points related to Virtue SAB:
-
A fundamentally different approach to sirolimus delivery, uptake, and extended release: Sirolimus is the proven antiproliferative drug with well-established safety and effectiveness, but its optimal benefit depends on achieving and sustaining sufficient drug concentrations in tissue through the healing period. Coating-based drug delivery is limited by dose, drug loss in transit, and uneven transfer and diffusion from the surface. Virtue SAB is designed to infuse a large liquid volume of submicron, particle-encapsulated SirolimusEFR directly into the vessel wall through a non-coated, microporous AngioInfusion Balloon to inhibit proliferation and modulate inflammation, the key drivers of restenosis.
-
Promising preclinical and clinical evidence: Published preclinical data showed that Virtue SAB achieved sirolimus tissue concentrations exceeding those of published drug-eluting stents and drug-coated balloons benchmarks through the critical healing period. In the SABRE study in coronary ISR, Virtue SAB achieved a low three-year target lesion failure rate of 14.3% in all treated patients (intent-to-treat analysis), with no additional target lesion revascularizations between years one and three.
-
The head-to-head, randomized design of the Virtue Trial: The Virtue Trial is a prospective, multicenter, randomized, single-blind, non-inferiority trial with a planned enrollment of approximately 740 patients comparing Virtue SAB with the commercially available AGENT™ paclitaxel-coated balloon.
Dr. Jeremias commented, “Patients with coronary in-stent restenosis frequently face renewed narrowing of a previously treated artery that requires another intervention. We need more durable treatment options that better address this recurring problem without adding another permanent layer of metal inside the artery. Virtue SAB offers the potential to achieve better vessel healing following intervention through optimized sirolimus drug delivery via balloon-based infusion. The Virtue Trial is an opportunity to determine whether this novel approach can translate into meaningful clinical benefit for patients. I look forward to sharing this innovative technology and the pivotal IDE trial design with the TCT community.”
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.
AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial, and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. The BACKBEAT Global Pivotal Trial evaluating AVIM Therapy in this population has completed enrollment.
Virtue SAB is a first-of-its-kind, non-coated drug delivery AngioInfusion balloon system designed to infuse a large liquid dose of a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB exceeded the published tissue concentrations of leading limus drug-eluting stents and demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multicenter, prospective, independent core laboratory–adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease, and below-the-knee peripheral artery disease, in each case, within specified parameters. The Virtue Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients.
CAUTION: Investigational device. Limited by United States law to investigational use.
October 22, 2026
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcast
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.
Orchestra BioMed leadership will be joined by key leading cardiologists to discuss the clinical and treatment burden associated with uncontrolled hypertension in pacemaker-indicated patients and restenosis in coronary stent interventions, as well as the potential for AVIM Therapy and Virtue SAB to address these unmet needs. The program will also highlight key upcoming clinical milestones and explore the commercial potential of AVIM Therapy and Virtue SAB.
R&D Day Agenda
3:00 PM | Opening Remarks Led by David Hochman, Chairman and Chief Executive Officer
3:10 PM | AVIM Therapy, BACKBEAT Pivotal Trial & Medtronic Strategic Collaboration Led by David Hochman & Avi Fischer, MD, Senior Vice President, Medical Affairs & Innovation Physician Speakers:
-
Vivek Reddy, MD, Executive Chairman of the BACKBEAT Trial Steering Committee, Director of Cardiac Arrhythmia Services, Mount Sinai Hospital and the Mount Sinai Health System
-
Marat Fudim, MD, Associate Professor of Cardiology, Advanced Heart Failure, Duke University Medical Center
4:20 PM | Virtue SAB & Virtue Pivotal Trial Led by Darren Sherman, President & Chief Operating Officer Physician Speakers:
-
Dean Kereiakes, MD, Virtue Trial Co-PI, Chairman of The Christ Hospital Heart and Vascular Institute, The Christ Hospital Health Network
-
Allen Jeremias, MD, Virtue Trial Co-PI, Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center, New York and an Executive Director for Optimizing PCI
5:15 PM | Q&A Closing Remarks Moderated by David Hochman and Darren Sherman
Registration and Webcast Information
The R&D Day will be held in person in New York City and streamed via live webcast, and available for replay following the event.
-
In-person attendance: Please register here. Space is limited, and the Company may not be able to accommodate all requests. In-person registrations are subject to written confirmation, and venue and event details will be provided upon confirmation.
-
Live webcast: Please register here to access the live webcast. A replay will be available on the Investors section of Orchestra BioMed’s website following the event.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. The BACKBEAT Global Pivotal Trial evaluating AVIM Therapy has completed enrollment.
AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations.
Virtue SAB is a first-of-its-kind, non-coated drug delivery Angioinfusion balloon system designed to infuse a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. The Virtue Pivotal Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Jan 27, 2023 | Renamed | HEALTH SCIENCES ACQUISITIONS CORP 2 → ORCHESTRA BIOMED HOLDINGS, INC. |







